ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and Investment Forum held on March 27, 2017 at the New York Academy of Sciences
(Thomson Reuters ONE) -
TORONTO, March 28, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences ("ProMIS" or
the "Company"), a company focused on the discovery and development of precision
treatments for neurodegenerative diseases, today announced its participation in
the 2nd Annual Neuroscience Biopartnering and Investment Forum conference
organized by Sachs Associates and held at the New York Academy of Sciences on
March 27, 2017.
ProMIS Executive Chairman, Eugene Williams, presented an update and overview on
the company's rapid progress and future outlook, and also contributed as a
member of the expert panel entitled "Advances in Alzheimer's Disease."
"Following on from the Company's successful fundraise announced in February of
this year, ProMIS will focus on progressing the development of its antibody
program targeting toxic, prion-like forms of Amyloid beta, a root cause of
Alzheimer's. Our lead development product, PMN310, is on track for IND
submission at the end of 2018," stated Williams. "Furthermore, there is a
substantial body of evidence from prior clinical trials in AD that targeting
specifically the toxic, prion-like strains of Amyloid beta, while avoiding
targeting of Amyloid beta monomer and plaque, will lead to best in class disease
modifying therapy."
The Company overview presented at the meeting is available on the ProMIS
Neurosciences website at:
http://bit.ly/2na9QPl
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision
medicine therapeutics for effective treatment of neurodegenerative diseases, in
particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platforms-ProMIS(TM) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has three preclinical monoclonal antibody
therapeutics against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
or contact
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="EnWave Signs Commercial Royalty-Bearing License With Bare Foods Co. for the Production of Healthy Snack ProductsDatum: 28.03.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 532934
Anzahl Zeichen: 5018
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 147 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and Investment Forum held on March 27, 2017 at the New York Academy of Sciences"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
